Mesa Laboratories, Inc. (NASDAQ:MLAB) Director John Bradley Schmieder Sells 1,000 Shares

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director John Bradley Schmieder sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $123.74, for a total value of $123,740.00. Following the completion of the transaction, the director now directly owns 62,760 shares in the company, valued at $7,765,922.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

John Bradley Schmieder also recently made the following trade(s):

• On Wednesday, September 13th, John Bradley Schmieder sold 3,000 shares of Mesa Laboratories stock. The stock was sold at an average price of $123.32, for a total transaction of $369,960.00.

Mesa Laboratories Stock Performance

Shares of NASDAQ:MLAB traded down $1.80 on Tuesday, reaching $119.86. 5,273 shares of the company’s stock were exchanged, compared to its average volume of 48,488. The firm has a market capitalization of $644.85 million, a price-to-earnings ratio of 368.68 and a beta of 0.72. Mesa Laboratories, Inc. has a fifty-two week low of $114.21 and a fifty-two week high of $206.36. The business’s 50-day moving average is $131.77 and its two-hundred day moving average is $146.56. The company has a quick ratio of 2.03, a current ratio of 2.93 and a debt-to-equity ratio of 0.45.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.09. Mesa Laboratories had a net margin of 0.83% and a return on equity of 9.36%. The business had revenue of $50.65 million during the quarter, compared to the consensus estimate of $51.85 million. As a group, equities research analysts forecast that Mesa Laboratories, Inc. will post 5.67 EPS for the current year.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Thursday, August 31st were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.53%. The ex-dividend date of this dividend was Wednesday, August 30th. Mesa Laboratories’s dividend payout ratio (DPR) is 193.95%.

Institutional Trading of Mesa Laboratories

Several hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its holdings in shares of Mesa Laboratories by 3.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 1,987 shares of the medical instruments supplier’s stock valued at $330,000 after acquiring an additional 57 shares during the period. Mackenzie Financial Corp lifted its position in Mesa Laboratories by 5.5% in the 1st quarter. Mackenzie Financial Corp now owns 1,183 shares of the medical instruments supplier’s stock valued at $302,000 after purchasing an additional 62 shares during the last quarter. Alliancebernstein L.P. boosted its stake in Mesa Laboratories by 0.4% during the 3rd quarter. Alliancebernstein L.P. now owns 14,479 shares of the medical instruments supplier’s stock valued at $2,039,000 after purchasing an additional 63 shares during the period. Arizona State Retirement System grew its position in Mesa Laboratories by 4.8% in the 4th quarter. Arizona State Retirement System now owns 1,500 shares of the medical instruments supplier’s stock worth $249,000 after purchasing an additional 69 shares during the last quarter. Finally, LPL Financial LLC grew its position in Mesa Laboratories by 5.5% in the 2nd quarter. LPL Financial LLC now owns 1,335 shares of the medical instruments supplier’s stock worth $272,000 after purchasing an additional 70 shares during the last quarter. Institutional investors own 91.06% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Mesa Laboratories in a report on Thursday, August 17th. They issued a “hold” rating for the company.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.